Mark, D B <br/><br/>
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.  [electronic resource] 

 -  The New England journal of medicine  May 1995 
 - 1418-24 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0028-4793 
<br/><br/><label>Standard No.: </label>10.1056/NEJM199505253322106  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Cerebrovascular Disorders--etiology<br/>Cost-Benefit Analysis<br/>Costs and Cost Analysis<br/>Drug Administration Schedule<br/>Humans<br/>Life Expectancy<br/>Middle Aged<br/>Myocardial Infarction--complications<br/>Prospective Studies<br/>Quality of Life<br/>Risk<br/>Streptokinase--economics<br/>Thrombolytic Therapy--economics<br/>Tissue Plasminogen Activator--economics